Plain-English translation of NCT07471789 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses your own immune cells that have been specially designed in the laboratory to fight blood cancer. The treatment works by training these cells to recognize and destroy cancer cells that have a specific marker called CD84. Researchers believe this approach could help patients whose cancers have stopped responding to standard chemotherapy.
Patients with relapsed or refractory AML and T-ALL have very few treatment options and poor outcomes with current therapies. This medication aims to fill that gap by using a cutting-edge approach that has shown promise in treating other blood cancers, offering hope to patients who have run out of conventional options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive an infusion of the specially designed immune cells after preparation with chemotherapy. You will then be monitored closely in the hospital and as an outpatient for safety and how well the treatment is working, with blood tests and scans to track your response. The trial is designed in two phases: the first focuses on safety and finding the right dose, and the second evaluates how well the treatment actually works against the cancer.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Spain